Induction of pancreatic cancer cell migration by an autocrine epidermal growth factor receptor activation

Experimental Cell Research

Volumn 326, Issue 2, 2014, Pages 307-314

  Stock, Anna Maria ^a   Hahn, Stephan A ^b   Troost, Gabriele ^a   Niggemann, Bernd ^a   Zänker, Kurt S ^a   Entschladen, Frank ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Cell migration; Epidermal growth factor; Metastasis; Pancreatic cancer; Receptor tyrosine kinases

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; AUTOANTIBODY; CYTOKINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR ANTIBODY; PROTEIN ANTIBODY; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ARTICLE; AUTOCRINE ACTIVATION; AUTOCRINE EFFECT; CANCER CELL; CELL MIGRATION; CELL MIGRATION ASSAY; CELL TRACKING; COLLAGEN BASED ASSAY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REDUCTION; THREE DIMENSIONAL IMAGING;

CELL MIGRATION; EPIDERMAL GROWTH FACTOR; METASTASIS; PANCREATIC CANCER; RECEPTOR TYROSINE KINASES;

ANTIBODIES, NEUTRALIZING; AUTOCRINE COMMUNICATION; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 84904762153     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.04.022     Document Type: Article

References (53)

1. Schnelldorfer T., Ware A.L., Sarr M.G., Smyrk T.C., Zhang L., Qin R., Gullerud R.E., Donohue J.H., Nagorney D.M., Farnell M.B. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?. Ann. Surg. 2008, 247:456-462.
2. Guo J., Lou W., Ji Y., Zhang S. Effect of CCR7, CXCR4 and VEGF-C on the lymph node metastasis of human pancreatic ductal adenocarcinoma. Oncol. Lett. 2013, 5:1572-1578.
3. Entschladen F., Drell T.L.t., Lang K., Joseph J., Zänker K.S. Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. Lancet Oncol. 2004, 5:254-258.
4. Kedrin D., van Rheenen J., Hernandez L., Condeelis J., Segall J.E. Cell motility and cytoskeletal regulation in invasion and metastasis. J. Mammary Gland Biol. Neoplasia 2007, 12:143-152.
5. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
6. Entschladen F., Zänker K.S., Powe D.G. Heterotrimeric G protein signaling in cancer cells with regard to metastasis formation. Cell Cycle 2011, 10:1086-1091.
7. Entschladen F., Drell T.L.t., Lang K., Joseph J., Zänker K.S. Neurotransmitters and chemokines regulate tumor cell migration: potential for a new pharmacological approach to inhibit invasion and metastasis development. Curr. Pharm. Des. 2005, 11:403-411.
8. Bastian P., Balcarek A., Altanis C., Strell C., Niggemann B., Zaenker K.S., Entschladen F. The inhibitory effect of norepinephrine on the migration of ES-2 ovarian carcinoma cells involves a Rap1-dependent pathway. Cancer Lett. 2009, 274:218-224.
9. Stock A.M., Troost G., Niggemann B., Zanker K.S., Entschladen F. Targets for anti-metastatic drug development. Curr. Pharm. Des. 2013.
10. Stock A.M., Powe D.G., Hahn S.A., Troost G., Niggemann B., Zanker K.S., Entschladen F. Norepinephrine inhibits the migratory activity of pancreatic cancer cells. Exp. Cell Res. 2013, 319:1744-1758.
11. Niggemann B., Drell T.L.t., Joseph J., Weidt C., Lang K., Zaenker K.S., Entschladen F. Tumor cell locomotion: differential dynamics of spontaneous and induced migration in a 3D collagen matrix. Exp. Cell Res. 2004, 298:178-187.
12. Strell C., Niggemann B., Voss M.J., Powe D.G., Zanker K.S., Entschladen F. Norepinephrine promotes the beta1-integrin-mediated adhesion of MDA-MB-231 cells to vascular endothelium by the induction of a GROalpha release. Mol. Cancer Res. 2012, 10:197-207.
13. Cadena D.L., Gill G.N. Receptor tyrosine kinases. FASEB J. 1992, 6:2332-2337.
14. Alonso G., Koegl M., Mazurenko N., Courtneidge S.A. Sequence requirements for binding of Src family tyrosine kinases to activated growth factor receptors. J. Biol. Chem. 1995, 270:9840-9848.
15. Lemoine N.R., Hughes C.M., Barton C.M., Poulsom R., Jeffery R.E., Kloppel G., Hall P.A., Gullick W.J. The epidermal growth factor receptor in human pancreatic cancer. J. Pathol. 1992, 166:7-12.
16. Kimura K., Sawada T., Komatsu M., Inoue M., Muguruma K., Nishihara T., Yamashita Y., Yamada N., Ohira M., Hirakawa K. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin. Cancer Res. 2006, 12:4925-4932.
17. Ebert M., Yokoyama M., Friess H., Kobrin M.S., Buchler M.W., Korc M. Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int. J. Cancer 1995, 62:529-535.
18. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.
19. Citri A., Yarden Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol. 2006, 7:505-516.
20. Seshacharyulu P., Ponnusamy M.P., Haridas D., Jain M., Ganti A.K., Batra S.K. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin. Ther. Targets 2012, 16:15-31.
21. Murphy L.O., Cluck M.W., Lovas S., Otvos F., Murphy R.F., Schally A.V., Permert J., Larsson J., Knezetic J.A., Adrian T.E. Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions. Br. J. Cancer 2001, 84:926-935.
22. Kim H.K., Kim J.W., Zilberstein A., Margolis B., Kim J.G., Schlessinger J., Rhee S.G. PDGF stimulation of inositol phospholipid hydrolysis requires PLC-gamma 1 phosphorylation on tyrosine residues 783 and 1254. Cell 1991, 65:435-441.
23. Meisenhelder J., Suh P.G., Rhee S.G., Hunter T. Phospholipase C-gamma is a substrate for the PDGF and EGF receptor protein-tyrosine kinases in vivo and in vitro. Cell 1989, 57:1109-1122.
24. Masur K., Lang K., Niggemann B., Zänker K.S., Entschladen F., High PKC alpha and low E-cadherin expression contribute to high migratory activity of colon carcinoma cells. Mol. Biol. Cell 2001, 12:1973-1982.
25. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
26. Hasina R., Matsumoto K., Matsumoto-Taniura N., Kato I., Sakuda M., Nakamura T. Autocrine and paracrine motility factors and their involvement in invasiveness in a human oral carcinoma cell line. Br. J. Cancer 1999, 80:1708-1717.
27. Riesco-Eizaguirre G., Rodriguez I., De la Vieja A., Costamagna E., Carrasco N., Nistal M., Santisteban P. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res. 2009, 69:8317-8325.
28. Darrington E., Zhong M., Vo B.H., Khan S.A. Vascular endothelial growth factor A, secreted in response to transforming growth factor-beta1 under hypoxic conditions, induces autocrine effects on migration of prostate cancer cells. Asian J. Androl. 2012, 14:745-751.
29. Lacal P.M., Ruffini F., Pagani E., D'Atri S. An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells. Int. J. Oncol. 2005, 27:1625-1632.
30. Krasagakis K., Garbe C., Zouboulis C.C., Orfanos C.E. Growth control of melanoma cells and melanocytes by cytokines. Recent Results Cancer Res. 1995, 139:169-182.
31. Singh B., Schneider M., Knyazev P., Ullrich A. UV-induced EGFR signal transactivation is dependent on proligand shedding by activated metalloproteases in skin cancer cell lines. Int. J. Cancer 2009, 124:531-539.
32. Bardeesy N., Kim M., Xu J., Kim R.S., Shen Q., Bosenberg M.W., Wong W.H., Chin L. Role of epidermal growth factor receptor signaling in RAS-driven melanoma. Mol. Cell Biol. 2005, 25:4176-4188.
33. Akslen L.A., Puntervoll H., Bachmann I.M., Straume O., Vuhahula E., Kumar R., Molven A. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res. 2008, 18:29-35.
34. de Wit P.E., Moretti S., Koenders P.G., Weterman M.A., van Muijen G.N., Gianotti B., Ruiter D.J. Increasing epidermal growth factor receptor expression in human melanocytic tumor progression. J. Invest. Dermatol. 1992, 99:168-173.
35. Mattei S., Colombo M.P., Melani C., Silvani A., Parmiani G., Herlyn M. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int. J. Cancer 1994, 56:853-857.
36. Sparrow L.E., Heenan P.J. Differential expression of epidermal growth factor receptor in melanocytic tumours demonstrated by immunohistochemistry and mRNA in situ hybridization. Australas. J. Dermatol. 1999, 40:19-24.
37. Meierjohann S., Wende E., Kraiss A., Wellbrock C., Schartl M. The oncogenic epidermal growth factor receptor variant Xiphophorus melanoma receptor kinase induces motility in melanocytes by modulation of focal adhesions. Cancer Res. 2006, 66:3145-3152.
38. Laisney J.A., Mueller T.D., Schartl M., Meierjohann S. Hyperactivation of constitutively dimerized oncogenic EGF receptors by autocrine loops. Oncogene 2013, 32:2403-2411.
39. Ioannou N., Dalgleish A.G., Seddon A.M., Mackintosh D., Guertler U., Solca F., Modjtahedi H. Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. Br. J. Cancer 2011, 105:1554-1562.
40. Uegaki K., Nio Y., Inoue Y., Minari Y., Sato Y., Song M.M., Dong M., Tamura K. Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res. 1997, 17:3841-3847.
41. Bloomston M., Bhardwaj A., Ellison E.C., Frankel W.L. Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig. Surg. 2006, 23:74-79.
42. Tobita K., Kijima H., Dowaki S., Kashiwagi H., Ohtani Y., Oida Y., Yamazaki H., Nakamura M., Ueyama Y., Tanaka M., Inokuchi S., Makuuchi H. Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int. J. Mol. Med. 2003, 11:305-309.
43. Tzahar E., Waterman H., Chen X., Levkowitz G., Karunagaran D., Lavi S., Ratzkin B.J., Yarden Y. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol. 1996, 16:5276-5287.
44. Graus-Porta D., Beerli R.R., Daly J.M., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997, 16:1647-1655.
45. Beerli R.R., Graus-Porta D., Woods-Cook K., Chen X., Yarden Y., Hynes N.E. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol. Cell. Biol. 1995, 15:6496-6505.
46. Graus-Porta D., Beerli R.R., Hynes N.E. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol. Cell. Biol. 1995, 15:1182-1191.
47. Ioannou N., Seddon A.M., Dalgleish A., Mackintosh D., Modjtahedi H. Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancer. Front. Biosci. 2012, 17:2698-2724.
48. Rocha-Lima C.M., Raez L.E. Erlotinib (tarceva) for the Treatment of Non-small-cell Lung Cancer and Pancreatic Cancer. P T 2009, 34:554-564.
49. Zaenker K.S., Entschladen F. Paving roads for new drugs in oncology. Recent Patents Anticancer Drug Discovery 2009, 4:137-145.
50. Ioannou N., Seddon A.M., Dalgleish A., Mackintosh D., Modjtahedi H. Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. BMC Cancer 2013, 13:41.
51. Kelley R.K., Ko A.H. Erlotinib in the treatment of advanced pancreatic cancer. Biologics 2008, 2:83-95.
52. Ostman A., Heldin C.H. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv. Cancer Res. 2001, 80:1-38.
53. Kawaguchi J., Adachi S., Yasuda I., Yamauchi T., Yoshioka T., Itani M., Kozawa O., Moriwaki H. UVC irradiation suppresses platelet-derived growth factor-BB-induced migration in human pancreatic cancer cells. Oncol. Rep. 2012, 27:935-939.